You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,435,869


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,435,869
Title:Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin
Abstract: A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glands of the animals and secreting the expressed product into a body fluid. Methodology employing such a mammal yields recombinant physiologically functional fibrinogens, subunit chain polypeptides thereof, and modified or fusion fibrinogens.
Inventor(s): Velander; William H. (Blacksburg, VA), Drohan; William N. (Springfield, VA), Lubon; Henryk (Rockville, MD), Johnson; John L. (Blacksburg, VA)
Assignee: Virgina Tech. Intellectual Properties, Inc. (Blacksburg, VA) American National Red Cross (Washington, DC) University of North Carolina at Chapel Hill (Chapel Hill, NC)
Application Number:11/040,117
Patent Claims:1. A method for producing biologically active fibrin comprising: providing a transgenic non-human mammal whose genome comprises a first DNA segment encoding a heterologous fibrinogen A.alpha. chain, a second DNA segment encoding a heterologous fibrinogen B.beta. chain, and a third DNA segment encoding a heterologous fibrinogen G.gamma. chain, wherein each of said first, second and third segments is operably linked to a cis-acting, expression promoter-containing regulatory sequence; allowing the expression of said first, second and third DNA segments in said mammal and the production of milk containing said biologically active fibrinogen; collecting milk from said mammal; recovering the fibrinogen from said milk; and converting the fibrinogen to fibrin by reacting the fibrinogen with thrombin.

2. The method of claim 1, wherein said conversion of fibrinogen to fibrin occurs in a subject which has been administered said fibrinogen.

3. A method for producing biologically active fibrin comprising: providing a transgenic non-human mammal whose genome comprises a first DNA segment encoding a heterologous fibrinogen A.alpha. chain, a second DNA segment encoding a heterologous fibrinogen B.beta. chain, and a third DNA segment encoding a heterologous fibrinogen G.gamma. chain, wherein each of said first, second and third segments is operably linked to a cis-acting, expression promoter-containing regulatory sequence; allowing the expression of said first, second and third DNA segments in said mammal and the production of milk containing biologically active fibrinogen; collecting milk from said mammal; recovering the fibrinogen from said milk; and converting the fibrinogen to fibrin by reacting the fibrinogen with at least one protease.

4. The method of claim 3, wherein said conversion of fibrinogen to fibrin occurs in a subject which has been administered said fibrinogen.

5. A method for producing biologically active fibrin comprising: recovering fibrinogen from the milk of a transgenic non-human mammal whose genome comprises a first DNA segment encoding a heterologous fibrinogen A.alpha. chain, a second DNA segment encoding a heterologous fibrinogen B.beta. chain, and a third DNA segment encoding a heterologous fibrinogen G.gamma. chain, wherein each of said first, second and third segments is operably linked to a cis-acting, expression promoter-containing regulatory sequence which allows the expression of said first, second and third DNA segments in said mammal; and converting the fibrinogen to fibrin by reacting the fibrinogen with at least one protease.

6. The method of claim 5, wherein said protease is thrombin.

7. The method of claim 6, wherein said conversion of fibrinogen to fibrin occurs in a subject which has been administered said fibrinogen.

8. A method for producing biologically active fibrinogen comprising: providing a female transgenic non-human mammal comprising stably integrated in its genome a first DNA segment encoding a first DNA segment encoding a heterologous fibrinogen A.alpha. chain, a second DNA segment encoding a second DNA encoding a heterologous fibrinogen B.beta. chain, and a third DNA segment encoding a third DNA encoding a heterologous fibrinogen G.gamma. chain, wherein each chain is derived from the same species, and wherein each of said first, second and third segments is operably linked to a promoter-containing regulatory sequence required for its expression in a mammary gland of a transgenic non-human mammal; allowing the expression of said first, second and third DNA segments and the assembly of the expressed individual A.alpha., B.beta. and G.gamma. polypeptides into biologically active fibrinogen in the cells of the mammary gland followed by the secretion of the biologically active fibrinogen into the milk of said female mammal; collecting milk from said mammal; and recovering the biologically active fibrinogen from the milk in concentrations of 30 .mu.g/ml or greater.

9. The method according to claim 8, wherein said transgenic non-human mammal is selected from the group consisting of a rodent, rabbit, sheep, pig, goat and cattle.

10. The method according to claim 8, wherein said promoter is a mammary gland specific promoter.

11. The method according to claim 10, wherein said promoter is selected from the group consisting of casein, .beta.-lactoglobulin, .alpha.-lactalbumin and whey acidic protein gene promoters.

12. The method according to claim 8, wherein said fibrinogen is human fibrinogen.

13. The method according to claim 8, wherein said first, second, and third DNA segments further comprises an intron.

14. A method for producing biologically active fibrinogen comprising: providing a first DNA segment encoding a heterologous fibrinogen A.alpha. chain, a second DNA segment encoding a heterologous fibrinogen B.beta. chain; and a third DNA segment encoding a heterologous fibrinogen G.gamma. chain, wherein each chain is from the same species, and wherein each of said first, second and third segments is operably linked to a promoter-containing regulatory sequence required for its expression in the mammary gland of a female transgenic non-human mammal; introducing said DNA segments into a fertilized egg of a non-human mammalian species heterologous to the species of origin of said fibrinogen chains; inserting said egg into an oviduct or uterus of a female of said mammalian species to obtain a transgenic non-human mammal whose genome comprises said DNA segments; breeding said mammal to produce female progeny that express said first, second and third DNA segments, wherein the assembly of the expressed individual A.alpha., B.beta. and G.gamma. polypeptides into biologically active fibrinogen occurs in the cells of the mammary gland followed by the secretion of the biologically active fibrinogen into the milk of said female mammal; collecting milk from said female progeny; and recovering the biologically active fibrinogen from the milk in concentrations of 30 .mu.g/ml or greater.

15. The method according to claim 14, wherein said transgenic non-human mammal is selected from the group consisting of a rodent, rabbit, sheep, pig, goat and cattle.

16. The method according to claim 14, wherein said first, second, and third DNA segments further comprises an intron.

17. The method according to claim 14, wherein said promoter is a mammary gland specific promoter.

18. The method according to claim 17, wherein said promoter is selected from the group consisting of casein, .beta.-lactoglobulin, .alpha.-lactalbumin and whey acidic protein gene promoters.

19. The method according to claim 14, wherein said fibrinogen is human fibrinogen.

20. A transgenic non-human mammal, wherein the genome of said mammal comprises: a first DNA segment encoding a heterologous fibrinogen A.alpha. chain; a second DNA segment encoding a heterologous fibrinogen B.beta. chain; and a third DNA segment encoding a heterologous fibrinogen G.gamma. chain; and wherein each chain is derived from the same species and is operably linked to a promoter-containing regulatory sequence required for its expression in the mammary gland of a host mammal, and wherein expression of said DNA segments and the assembly of the expressed individual A.alpha., B.beta. and G.gamma. polypeptides into biologically active fibrinogen occurs in the cells of the mammary gland followed by the secretion of the biologically active fibrinogen into the milk, if said mammal is female, resulting in the production of recoverable quantities of biologically active fibrinogen from milk of said non-human mammal in concentrations of 30 .mu.g/ml or greater.

21. The non-human transgenic mammal according to claim 20, wherein said non-human mammal is selected from the group consisting of a rodent, rabbit, sheep, pig, goat and cattle.

22. The method according to claim 20, wherein said promoter is a mammary gland specific promoter.

23. The non-human transgenic mammal according to claim 22, wherein said promoter is selected from the group consisting of casein, .beta.-lactoglobulin, .alpha.-lactalbumin and whey acidic protein gene promoters.

24. The non-human mammal according to claim 20, wherein said mammal is female.

25. The non-human mammal according to claim 20, wherein said mammal is male.

26. The method according to claim 20, wherein said first, second, and third DNA segments further comprises an intron.

27. The method according to claim 20, wherein said fibrinogen is human fibrinogen.

28. A process for producing a transgenic non-human mammal comprising: providing a first DNA segment encoding a first DNA encoding a heterologous fibrinogen A.alpha. chain, a second DNA segment encoding a second DNA encoding a heterologous fibrinogen B.beta. chain, and a third DNA segment encoding a third DNA encoding a heterologous fibrinogen G.gamma. chain, wherein each chain is derived from the same species, and wherein each of said first, second and third segments is operably linked to a promoter-containing regulatory sequence required for its expression in a mammary gland of a host female mammal; introducing said DNA segments into a fertilized egg of a non-human species heterologous to the species of origin of said fibrinogen chains; inserting said fertilized egg into an oviduct or uterus of a female of said mammalian species; and allowing said fertilized egg to develop thereby producing a transgenic non-human mammal whose genome comprises said first, second and third DNA segments, which are expressed as individual A.alpha., B.beta. and G.gamma. polypeptides that are assembled into biologically active fibrinogen in the cells of the mammary gland followed by the secretion of the biologically active fibrinogen into the milk, if said mammal is a female progeny, resulting in the production of recoverable quantities of biologically active fibrinogen from milk of said female progeny in concentrations of 30 .mu.g/ml or greater.

29. The process according to claim 28, wherein said mammal is female.

30. The process according to claim 28, wherein said mammal is male.

Details for Patent 7,435,869

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2014-02-18
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2014-02-18
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2014-02-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.